3D illustration of Heart - Part of Human Organic.

The Role of PCSK9 Inhibitors in Reducing CV Risk: Patient Selection Criteria and Treatment Initiation Tactics

http://academiccme.com/wp-content/uploads/2018/08/Giugliano-Module-2-wpcf_400x400.jpg

Course Information

Therapautic Area: Cardiology
Format(s): Webcast
Credit(s): 0.50 AMA PRA Category 1 Credit™
Activity Dates: September 5, 2018 - September 4, 2019

 

Program Overview

In this module of a Four-Part Expert Interview Series, Dr. Robert P. Giugliano, along with Dr Christopher P. Cannon, course chair, will examine the role of PCSK9 inhibitors in reducing CV risk. Dr. Guigliano will review optimal patient selection criteria and how it can be applied in daily practice. This module will allow learners to understand the relationship between LDL-C and risk of a cardiovascular event.

Target Audience

Cardiologists, internists, and other healthcare professionals involved in the management of patients with dyslipidemia

Learning Objectives


1. Understand the relationship between LDL-C and risk of a cardiovascular event
2. Utilize optimal patient selection criteria and treatment initiation tactics in clinical practice

Faculty

Cannon Head ShotChristopher P. Cannon, MD
Director, Education, Cardiovascular Medicine Innovation
Cardiovascular Division, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

 

 

Giugliano HeadshotRobert P. Giugliano, MD, SM
Senior Investigator, TIMI Study Group
CV Medicine, Brigham and Women’s Hospital
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Faculty Relationship Identified With:
Christopher P. Cannon, MD Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Janssen Global Services, LLC; Kowa Company, Ltd.; Merck & Co.; Pfizer Inc.; Regeneron; SanofiGrant/Research Support: Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; Janssen Global Services, LLC; Merck & Co.
Robert P. Giugliano, MD, SM Consultant/Advisor: Amarin Corporation; Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVS Caremark; Daiichi Sankyo Company Limited; GlaxoSmithKline; Lexicon Pharmaceuticals, Inc.; Merck & Co.; Portola Pharmaceuticals, Inc.; Pfizer Inc.Grant/Research Support: Amgen Inc.


Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation


1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Physicians who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CE Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.

BUTTON


Provided by: AcademicCME-web